BIB.US ProShares Ultra Nasdaq Biotechnology
- Total assets
- 107M
- Expense ratio
- 0.95%
- Dividend yield
- 0.19%
- 1-year return
- +65.81%
- Holdings
- 245
- Since
- 2010
Fund data as reported by the issuer, updated Nov 14, 2026. Total assets are in the fund's base currency.
What does BIB.US invest in?
- Mostly US stocks (63.4%)
- Largest sector: Healthcare (100.0%)
- Largest region: North America (99.1%)
- Top 3 holdings: 25.5% of the fund
Asset allocation
- US stocks 63.4%
- Cash 24.1%
- Other 10.7%
- Non-US stocks 3.4%
Top holdings
- Proshares Genius Money Market ETF 15.14%
- Gilead Sciences Inc 5.32%
- Amgen Inc 5.03%
- Vertex Pharmaceuticals Inc 4.96%
- Moderna Inc 3.90%
ProShares Ultra Nasdaq Biotechnology performance
Sharpe ratio 1.06- This year
- +53.08%
- 1 year
- +65.81%
- 3 years
- +42.95%
- 5 years
- +8.00%
Volatility 31.6% over 1 year and 33.4% over 3 years. High: expect large swings.
Total returns in the fund's currency as reported by the issuer; past returns do not predict future returns. Volatility is the yearly standard deviation of returns. Ask AI to explain these numbers
BIB.US price
Prices on the chart can differ slightly from the closing prices StockSummer shows.
About ProShares Ultra Nasdaq Biotechnology
The index is designed to measure the performance of a set of Nasdaq-listed biotechnology and pharmaceutical companies. Under normal circumstances, the fund will obtain leveraged exposure to at least 80% of its total assets in components of the index or in instruments with similar economic characteristics. The fund is non-diversified.
Full fund profileProShares Ultra Nasdaq Biotechnology top holdings
43.6% of the fund| Holding | Sector | Country | Weight |
|---|---|---|---|
| Proshares Genius Money Market ETF IQMM.US | - | United States | 15.14% |
| Gilead Sciences Inc GILD.US | Healthcare | United States | 5.32% |
| Amgen Inc AMGN.US | Healthcare | United States | 5.03% |
| Vertex Pharmaceuticals Inc VRTX.US | Healthcare | United States | 4.96% |
| Moderna Inc MRNA.US | Healthcare | United States | 3.90% |
| Regeneron Pharmaceuticals Inc REGN.US | Healthcare | United States | 3.50% |
| Revolution Medicines Inc RVMD.US | Healthcare | United States | 1.69% |
| Biogen Inc BIIB.US | Healthcare | United States | 1.45% |
| Illumina Inc ILMN.US | Healthcare | United States | 1.32% |
| Royalty Pharma Plc RPRX.US | Healthcare | United States | 1.25% |
The 10 largest of 245 holdings.
BIB.US sector exposure
- Healthcare100.0%
Share of the stocks in the fund.
BIB.US regional exposure
- North America99.1%
- Europe Developed2.2%
- United Kingdom2.1%
- Asia Emerging0.1%
- Australasia0.0%
- Africa/Middle East0.0%
- Asia Developed0.0%
Share of the stocks in the fund.
Company size
Average market cap 30.0B- Mega cap0.4%
- Big cap19.9%
- Medium cap18.2%
- Small cap13.7%
- Micro cap6.7%
ProShares Ultra Nasdaq Biotechnology fund profile
- Fund name
- ProShares Ultra Nasdaq Biotechnology
- Ticker
- BIB.US
- Exchange
- USA Stocks
- Issuer
- ProShares
- Fund website
- proshares.com/funds/bib.html
- Index tracked
- -
- Category
- Leveraged & Inverse Equity
- Domicile
- United States
- Inception date
- Apr 6, 2010
- Trading currency
- USD
- Expense ratio
- 0.95%
- Annual turnover
- 0.2%
About ProShares Ultra Nasdaq Biotechnology
The index is designed to measure the performance of a set of Nasdaq-listed biotechnology and pharmaceutical companies. Under normal circumstances, the fund will obtain leveraged exposure to at least 80% of its total assets in components of the index or in instruments with similar economic characteristics. The fund is non-diversified.